ImageneBio Inc
HealthcareNASDAQ:IMA · NASDAQ Global Market
-$0.09 today
Vol 0.01M · Avg 0.35M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.1%
avg -0.8%
ROIC
-33.4%
avg -58.6%
ROA
-29.6%
avg -48.5%
Analysis
ROA is currently the strongest return metric at -29.6% versus its period average of -48.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kristin Yarema | Chief Executive Officer, Director & Interim Principal Financial Officer | $710,348.00 | — | 55 | $128,100.00 | 1.14% |
Benjamin Porter-Brown | Chief Medical Officer | $588,361.00 | — | 53 | $0.00 | <0.01% |
Kurinji Pandiyan | Chief Strategy & Operations Officer | — | — | — | — | — |
Renuka Sivendran | Chief Technical Officer | — | — | — | — | — |
Bob Lally | Senior VP of Finance & Operations and Principal Accounting Officer | — | — | 63 | $58,778.00 | 0.52% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$10.60M
Sells
0
$0.00
Net Sentiment
+$10.60M
Net buying
Most Active
Bonita David P
3 transactions
Analysis
Insiders reported 7 buys worth $10.60M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $10.60M. Bonita David P was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +4.3% | +3.5% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.3% over three years. Forward estimates point to Revenue at +3.5% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
Metagenomi, Inc. Common Stock
MGX
$45.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages IMA?
ImageneBio Inc (IMA) lists 5 active executives. The top listed executive is Kurinji Pandiyan, Chief Strategy & Operations Officer.
Are IMA insiders buying or selling?
Recent insider activity shows net buying of $18.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.